{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:52:33Z","timestamp":1786978353881,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>It has been recognized that adding omalizumab to standard of care (SOC) is a promising treatment for pediatric moderate to severe asthma patients in the Chinese setting, as shown by a previous multicenter retrospective study. Nevertheless, there is as yet no concrete evidence of its economic advantages. Several international studies conducted in different countries have shown varying results. The study is designed to better demonstrate the economic impact of omalizumab for Chinese children with asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on consultation with physicians, a three\u2010state Markov model was developed. The progress of asthma is modeling using the states \u201cno symptoms,\u201d \u201csecondary control, no asthmatic attack\u201d and \u201casthmatic attack.\u201d To better reflect clinical treatment, exacerbation state was further divided into \u201cexacerbation with outpatient service\u201d and \u201cexacerbation with hospitalization.\u201d To understand the effects of treatment, the response rate of omalizumab was also modeled. The modeling cycle length was set at 1 week over a 5\u2010year time horizon. Clinical effect and transition probabilities were sourced from published literature, while cost data were primarily obtained from local databases. Cost\u2010effectiveness analysis was assessed from the health system perspective. One\u2010way sensitivity analyses and scenario analysis were performed to ensure the robustness of the results. The willingness\u2010to\u2010pay (WTP) threshold was set at 1 GDP\/capital, as recommended by the national guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>It was shown that adding omalizumab to SOC treatment would increase both the total cost and quality\u2010adjusted life years (QALYs) over 5 years, with an incremental cost\u2010effectiveness ratio (ICER) of CNY 111,644.77\/QALY, which is higher than the WTP threshold. Among the parameter variations, the two factors that altered the results were the proportion of hospitalizations in SOC therapy during asthma exacerbation and the weekly cost of omalizumab with full dose, which were both negatively correlated with the ICER. Scenario analysis, simulating the Medicare reimbursement conditions, reduced the ICER to an acceptable level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adding omalizumab to SOC treatment in pediatric moderate to severe asthma patients would be a cost\u2010effective choice under the current medical insurance reimbursement policy in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ppul.71066","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:45:11Z","timestamp":1743353111000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2010Effectiveness Analysis of Omalizumab Combined With Standard of Care in Treating Moderate to Severe Asthma Children in China"],"prefix":"10.1002","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-9244","authenticated-orcid":false,"given":"Wang","family":"Cao","sequence":"first","affiliation":[{"name":"Clinical Research Center, National Center for Children's Health, Beijing Children's Hospital Capital Medical University Beijing China"},{"name":"Department of Pharmacy National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-9752","authenticated-orcid":false,"given":"Yuncui","family":"Yu","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Center for Children's Health, Beijing Children's Hospital Capital Medical University Beijing China"},{"name":"Department of Pharmacy National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[{"name":"National Health Development Research Center National Health Commission Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Morton","sequence":"additional","affiliation":[{"name":"Saw Swee Hock School of Public Health National University of Singapore Singapore Singapore"},{"name":"Department of Management Science Strathclyde Business School, University of Strathclyde Glasgow Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Allergy National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Center for Children's Health, Beijing Children's Hospital Capital Medical University Beijing China"},{"name":"Department of Pharmacy National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Center for Children's Health, Beijing Children's Hospital Capital Medical University Beijing China"},{"name":"Department of Pharmacy National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China"},{"name":"Key Laboratory of Major Diseases in Children, Ministry of Education, National Center for Children's Health, Beijing Children's Hospital Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Institute for Health Metrics and Evaluation \u201cThe GBD Results Tool \u201d (2022).https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0276-7"},{"issue":"2","key":"e_1_2_11_4_1","first-page":"235","article-title":"Disease Burden of Asthma Among Children and Adolescents in China, 1990\u20102019","volume":"44","author":"Na Y.","year":"2023","journal-title":"Chinese Journal of Epidemiology"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2016.1144199"},{"key":"e_1_2_11_6_1","unstructured":"Global initiative for Asthma \u201cGlobal Strategy for Asthma Management and Prevention (2024 Update) \u201d (2024).www.ginasthma.org."},{"issue":"12","key":"e_1_2_11_7_1","first-page":"1023","article-title":"Guidelines for Bronchial Asthma Prevent and Management (2020 Edition)","volume":"43","author":"Asthma Group of Chinese Thoracic Society","year":"2020","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1395734"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.01.011"},{"issue":"12","key":"e_1_2_11_11_1","first-page":"881","article-title":"Expert Consensus on the Clinical Application of Omalizumab in Children With Allergic Asthma","volume":"36","author":"National Clinical Medical Research Center for Respiratory Diseases, Respiratory Group Asthma Collaboration Group, Pediatrics Branch of Chinese Medical Association, Pediatric Specialty Committee of Chinese Medical Education Association, etc","year":"2021","journal-title":"Chinese Journal of Practical Pediatrics"},{"issue":"4","key":"e_1_2_11_12_1","first-page":"341","article-title":"Chinese Expert Consensus on the Use of Omalizumab in Allergic Asthma (2021 Version)","volume":"45","author":"Chinese Thoracic Society Asthma Group","year":"2022","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25541"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26647"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2018.1544642"},{"issue":"2","key":"e_1_2_11_16_1","first-page":"111","article-title":"Treatment of Omalizumabon Allergic Asthma in Children and Adolescents: A Systematic Review","volume":"38","author":"Wang Y.","year":"2021","journal-title":"Chinese Journal of Drug Evaluation"},{"issue":"1","key":"e_1_2_11_17_1","first-page":"64","article-title":"Evaluation of the Effectiveness and Safety of Omalizumab in Children With Allergic Asthma: A Retrospective Multicenter Study in Real\u2010World China","volume":"38","author":"Xiang L.","year":"2023","journal-title":"Chinese Journal of Practical Pediatrics Clinical Journal"},{"issue":"12","key":"e_1_2_11_18_1","first-page":"40","article-title":"Discusion on the Calculation of Markov Model Transition Probability in Pharmacoeconomics Evaluation","volume":"36","author":"Zhou T.","year":"2017","journal-title":"Chinese Health Economics"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.09.042"},{"key":"e_1_2_11_20_1","volume-title":"China Guidelines for Pharmacoeconomic Evaluations (2020)","author":"Liu G. E.","year":"2020"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1660539"},{"key":"e_1_2_11_22_1","unstructured":"Department of Drug Policy and Essential Medicine National Health Commission of the People's Republic of China \u201cGuidelines for the Management of Comprehensive Clinical Evaluation of Drugs \u201d (2021).http:\/\/www.nhc.gov.cn\/yaozs\/s2908\/202107\/532e20800a47415d84adf3797b0f4869.shtml."},{"key":"e_1_2_11_23_1","unstructured":"China National Development Research Center National Center for Children's Health (China) \u201cMethod Guide for Pediatric Drug Evaluation \u201d (2022) http:\/\/www.nhei.cn\/nhei\/znfb\/202206\/c01d87a290664b01bf42a9dad769d69f.shtml."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2012.717659"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.756398"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0402-2"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta17520"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01216-9"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00954-y"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.71066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:28:56Z","timestamp":1745825336000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.71066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/ppul.71066"],"URL":"https:\/\/doi.org\/10.1002\/ppul.71066","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2024-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71066"}}